Given the need to improve the efficacy of standard-of-care immunotherapy (anti-CTLA-4 + anti-PD-1) in human malignant pleural mesothelioma (hMPM), we thoroughly characterized the immunobiology of the
**ASA = American Society of Anesthesiologists Score; *** Mortality: untill discharged or death.Cathegorical variables were analyzed by Chi-square or Fisher's exact test and compare means by Wilcoxon t